Table 2.
Clinical characteristics by any autoimmune conditions*
| No autoimmune condition | Any autoimmune condition | |||||
|---|---|---|---|---|---|---|
| Characteristic | N | % | N | % | P | |
| Sex | Male | 1213 | 57.0% | 112 | 41.3% | < 0.001 |
| Female | 915 | 43.0% | 159 | 58.7% | ||
| Age | ≤ 60 Years | 1071 | 50.3% | 108 | 39.9% | 0.001 |
| > 60 Years | 1057 | 49.7% | 163 | 60.1% | ||
| Performance Status | < 2 | 2002 | 94.1% | 249 | 91.9% | 0.16 |
| ≥ 2 | 126 | 5.9% | 22 | 8.1% | ||
| Prognostic Index | Low-intermediate risk | 1874 | 88.1% | 243 | 89.7% | 0.44 |
| High risk | 254 | 11.9% | 28 | 10.3% | ||
| Comorbidities | No | 1543 | 72.5% | 179 | 66.1% | 0.08 |
| Yes | 237 | 11.1% | 38 | 14.0% | ||
| Missing | 348 | 16.4% | 54 | 19.9% | ||
| Smoking | Never | 971 | 45.6% | 119 | 43.9% | < 0.001 |
| Former | 542 | 25.5% | 94 | 34.7% | ||
| Current | 160 | 7.5% | 26 | 9.6% | ||
| Missing | 455 | 21.4% | 32 | 11.8% | ||
| Subtype | DLBCL | 646 | 30.4% | 90 | 33.2% | < 0.001 |
| FL | 639 | 30.0% | 64 | 23.6% | ||
| MZL | 247 | 11.6% | 55 | 20.3% | ||
| MCL | 173 | 8.1% | 20 | 7.4% | ||
| HL | 275 | 12.9% | 22 | 8.1% | ||
| TCL | 148 | 7.0% | 20 | 7.4% | ||
*Based on self-report. DLBCL diffuse large B-cell lymphoma, HL Hodgkin lymphoma, IPI International Prognostic Index, MALT mucosa-associated lymphoid tissue, MCL mantle cell lymphoma, MZL marginal zone lymphoma, PS performance status, TCL T-cell lymphoma